New drug combo aims to wipe out leukemia cells in younger patients

NCT ID NCT02251548

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times

Summary

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (FCR) can eliminate all traces of leukemia in younger, previously untreated patients with chronic lymphocytic leukemia (CLL). About 85 participants will receive the combination and then be monitored for deep remission. The goal is to see if this approach leads to long-term disease control without the need for ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • University of Kansas Cancer Center

    Westwood, Kansas, 66205, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Coral Gables, Florida, 33146, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Deerfield Beach, Florida, 33442, United States

  • Unversity of Miami Sylvester Comprehensve Cancer Center

    Miami, Florida, 33136, United States

  • West Michigan Cancer Center

    Kalamazoo, Michigan, 49007, United States

Conditions

Explore the condition pages connected to this study.